DBV Technologies files BLA with FDA for Viaskin Peanut Patch

DBV Technologies has submitted a Biologics License Application (BLA) to the US Food and Drug Administration for the Viaskin Peanut Patch, targeting children aged 4 through 7 years with peanut allergy. The Franco-American biopharmaceutical company, listed on both Euronext Paris and Nasdaq, has simultaneously requested Priority Review, which if granted would shorten the standard FDA review clock from twelve months to six.

The BLA is underpinned by data from the VITESSE Phase 3 trial, a randomised, double-blind, placebo-controlled study enrolling 654 children across 86 sites in the United States, Canada, the United Kingdom, Europe, and Australia. DBV describes VITESSE as the largest immunotherapy clinical trial conducted to date in this age group. Children were randomised 2:1 to receive either the active 250-microgram patch or placebo over a twelve-month double-blind period, with a primary endpoint measuring the proportion of treatment responders in each arm. A subsequent open-label extension allows all participants to continue on the active patch for up to three years in total.

The technology and its distinction

The Viaskin Patch delivers allergen protein through intact skin via epicutaneous immunotherapy (EPIT), an approach that avoids both oral dosing and injection. DBV argues this non-invasive route leverages the skin's immune-tolerising properties to progressively desensitise children to peanut allergen. The FDA previously granted Breakthrough Therapy Designation to the patch, a designation that provides more intensive agency guidance during development and is generally regarded as a positive signal for review.

Chief executive Daniel Tassé described the BLA submission as "a significant milestone in DBV's transformation into a commercial organisation," adding that the filing reflects collaboration with the food allergy community and constructive engagement with the FDA over recent months.

Market context and competitive landscape

Peanut allergy affects an estimated one to two per cent of children in Western countries, and severe reactions carry life-threatening risk. The approved treatment landscape for paediatric peanut allergy remains limited. Aimmune Therapeutics' oral immunotherapy Palforzia, acquired by Nestlé Health Science and approved by the FDA in 2020 for patients aged 4 and above, is currently the only approved peanut immunotherapy in the United States. Palforzia requires daily oral dosing and carries a risk of gastrointestinal adverse events, a profile that has constrained uptake in clinical practice.

DBV's patch-based delivery is positioned as a more tolerable alternative, and clinical acceptance of epicutaneous dosing could prove commercially meaningful if the FDA approves the product. Several academic centres and biotech startups are also pursuing next-generation food-allergy desensitisation approaches, including sublingual formats and combination biologics, though none has reached BLA stage for peanut allergy in this age band.

The Priority Review request is commercially significant: a six-month review cycle would, if granted, put a potential PDUFA decision date in the first half of 2027, ahead of typical timelines. DBV also has an ongoing trial of the Viaskin Peanut Patch in toddlers aged 1 through 3, suggesting a broader label ambition if the 4-to-7 cohort secures approval first. Investors will be watching whether the FDA accepts the BLA for filing, which is typically confirmed within 60 days of submission, and whether Priority Review is formally granted at that stage.